{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"groups":[{"description":"GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen\n\nGDPT regimen: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.","id":"OG000","title":"GDPT Regimen"},{"description":"CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen\n\nCHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.","id":"OG001","title":"CHOP Regimen"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to end of follow-up-phase (approximately 24 months)","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"participants"}